Related Experiment Videos
Evaluation of ondansetron as a drug for premedication
1Clinic Anesthesiology and Intensive Care, Emergency Medical Institute, Pirogov, Sofia, Bulgaria.
Abstract:
The potency of Ondansetron (Zofran, Glaxo), a highly specific 5HT3 antagonist in preventing the very unfavorable complication during introducing anesthesia, i.e. a Bezold-Jarisch reflex-like reaction, was studied in a clinical trial. A total of 20 patients (12 males and 8 females aged 19-65 years) admitted for clinical surgical treatment participated in the trial. Zofran (8 mg in 500 ml Ringer solution) was injected intravenously one hour before intubation at a flow rate of 8 ml. min-1. Systolic and diastolic blood pressure, central venous pressure, breathing frequency and minute ventilation, pCO2 and pO2 in venous blood, electrocardiogram monitoring (ECG) and several common features such as spontaneous muscle activity, palpebral reflexes, skin and mucose surfaces were continuously observed. Visual, auscultatory and X-ray control of the lungs was effected. It was found that blockade of 5HT3 receptors prevented the appearance of Bezold-Jarisch reflex-like reaction. The drug could successfully be used in anesthesiological practice.
Insights
Ondansetron (Zofran) effectively prevents Bezold-Jarisch reflex-like reactions during anesthesia by blocking 5HT3 receptors. This study demonstrates its successful application in anesthesiology practice.
Area of Science:
- Anesthesiology
- Pharmacology
- Cardiovascular Physiology
Background:
- The Bezold-Jarisch reflex is a significant complication during anesthesia induction.
- 5HT3 receptor antagonists offer a potential prophylactic mechanism.
Purpose of the Study:
- To evaluate the efficacy of Ondansetron (Zofran) in preventing Bezold-Jarisch reflex-like reactions.
- To assess the safety and utility of Ondansetron in anesthesiological practice.
Main Methods:
- A clinical trial involving 20 patients undergoing surgical treatment.
- Intravenous administration of Ondansetron (8 mg) one hour prior to intubation.
- Continuous monitoring of hemodynamic parameters, respiratory function, ECG, and clinical signs.
Main Results:
- Blockade of 5HT3 receptors with Ondansetron successfully prevented Bezold-Jarisch reflex-like reactions.
- No adverse events related to the drug administration were reported.
Conclusions:
- Ondansetron is a potent 5HT3 antagonist effective in preventing anesthesia-induced cardiovascular complications.
- The drug demonstrates significant potential for safe and successful use in anesthesiology.